Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases

Blood

Volumn 95, Issue 3, 2000, Pages 783-789

  Federico, Massimo ^a   Vitolo, Umberto ^b   Zinzani, Pier Luigi ^b   Chisesi, Teodoro ^b   Clò, Vera ^b   Bellesi, Giampiero ^b   Magagnoli, Massimo ^b   Liberati, Marina ^b   Boccomini, Carola ^b   Niscola, Pasquale ^b   Pavone, Vincenzo ^b   Cuneo, Antonio ^b   Santini, Gino ^b   Brugiatelli, Maura ^b   Baldini, Luca ^b   Rigacci, Luigi ^b   Resegotti, Luigi ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LACTATE DEHYDROGENASE; SERUM ALBUMIN;

ADULT; ARTICLE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

ADULT; AGED; BLOOD SEDIMENTATION; COMBINED MODALITY THERAPY; FEMALE; FEVER; HUMANS; ITALY; L-LACTATE DEHYDROGENASE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; SERUM ALBUMIN; SURVIVAL RATE; SWEATING; TUMOR MARKERS, BIOLOGICAL; WEIGHT LOSS;

EID: 12944283270     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Armitage JO, Weisenburger DD, for the Non Hodgkin's Lymphoma Classification Project. New approach to classify non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol. 1998;16:2780.
2. Horning SI. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993;20:75.
3. Hoppe RT, Kushian P, Kaplan HS, Rosenberg SA, Brown BW. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood. 1981;58:592.
4. Lister TA, Cullen MH, Beard ME, et al. Comparison of combined and single agent chemotherapy in non-Hodgkin's lymphoma of favorable histological type. Br Med J. 1978;1:533.
5. Rosenberg SA. The low-grade non-Hodgkin's lymphomas: challenges and opportunities. J Clin Oncol. 1985;3:299.
6. Dana BW, Dahlberg S, Nathwani BN, et al. Long term follow-up of patients with low grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol. 1993;11:644.
7. Baldini L, Guffanti A, Gobbi P, et al. A pilot study on the use of the ProMACE-CytaBOM regimen as a first line treatment of advanced follicular non Hodgkin's lymphoma. Cancer. 1997;79:1234.
8. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311:1471.
9. Young RC, Longo DL, Glastein E, Ihde DC, Jaffe ES, DeVita VT Jr. The treatment of indolent lymphomas: Watchful waiting vs aggressive combined modality treatment. Semin Hematol. 1988; 25:11.
10. Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986;4:1470.
11. Litam P, Swan F, Cabanillas F, et al. Prognostic value of serum beta-2 microglobulin in low grade lymphoma. Ann Intern Med. 1991;114:855.
12. Soubeyran P, Eghbali H, Bonichon F, Trojani M, Richaud P, Hoerni B. Low-grade follicular lymphoma: analysis of prognosis in a series of 281 patients. Eur J Cancer Clin Oncol. 1991;27:1606.
13. Coiffier B, Bastion Y, Berger F, Felman P, Bryon PA. Prognostic factors in follicular lymphomas. Semin Oncol. 1993;20:89.
14. Bastion Y, Berger F, Bryon PA, Felman P, French M, Coiffier B. Follicular lymphomas: Assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol. 1991;2:123.
15. The Non-Hodgkin's Lymphoma Prognostic Factors Project. Development of a predictive model for aggressive lymphoma: The International NHL Prognostic Factors Project. N Engl J Med. 1993; 329:987.
16. Leonard RC, Hayward RL, Prescott RJ, Wang JX. The identification of discrete prognostic groups in low-grade non-Hodgkin's lymphoma. Ann Oncol. 1991;2:655.
17. Romaguera JE, McLaughlin P, North L, et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model. J Clin Oncol. 1991;9:762.
18. Cameron DA, Leonard RC, Mao JH, Prescott RJ. Identification of prognostic groups in follicular lymphoma. Leuk Lymphoma. 1993;10:89.
19. Lopez-Guillermo A, Montserrat E. Bosch F, Terol MJ, Campo E, Rozman C. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol. 1994;12:1343.
20. Bagley CH, De Vita VT, Berard CW, Canellos GT. Advanced lymphosarcoma: intensive cyclic combination chemotherapy with cyclophosphamide, vincristine and prednisolone. Ann Intern Med. 1972;76:272.
21. Mc Kelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484.
22. Nie HH, Hadlai H, Jenkins JG, Steinbrenner K, Bent DH. SPSS (Statistical Package for the Social Sciences). New York, NY: McGraw-Hill; 1979.
23. Gobbi PG, Gendarini A, Crema A, et al. Serum albumin in Hodgkin's disease. Cancer. 1985;55: 389.
24. Bloomfield CD, Goldman A, Dick F, Brunning RD, Kennedy BJ. Multivariate analysis of prognostic factors in the non-Hodgkin's malignant lymphomas. Cancer. 1974;33:870.
25. Steward W, Crowther D, McWilliam LJ, et al. Maintenance chlorambucil after CVP in the management of advanced stage, low grade histological type non-Hodgkin's lymphoma. Cancer. 1988; 61:441.
26. Gobbi PG, Cavalli C, Federico M, et al. Hodgkin's disease prognosis: a directly predictive equation. Lancet. 1988;26:675.
27. Rohatiner AZ, Johnson PW, Price CG, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol. 1994;12: 1177.
28. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO. High dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's Lymphoma. J Clin Oncol. 1997;15:445.
29. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphomas. Clin Oncol. 1996;14:1262.
30. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997:90: 2188.
31. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974.
32. Freedman AS, Gribben JG, Neuberg D, et al. High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996;88: 2780.
33. Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood. 1993;81:3449.
34. Corradini P, Astolfi M, Cherasco C, et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high dose chemotherapy and peripheral blood progenitor cell autografting. Blood. 1997;89:724.
35. Price CG, Meerabux J, Murtagh S, et al. The significance of circulating cells carrying t(14:18) in long remission from follicular lymphoma. J Clin Oncol. 1991;9:1527.
36. Zinzani PL, Baccini C, Zaccaria A, et al. Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma. Eur J Haematol. 1996;57: 355.
37. Christiansen I, Gidlof C, Kalkner KM, Hagberg H, Bennmarker H, Totterman T. Elevated serum levels of soluble ICAM-1 in non Hodgkin's lymphomas correlate with tumor burden, disease activity and other prognostic markers. Br J Haematol. 1996;92:639.
38. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 1997;90:3167.